Johnson & Johnson stock reports durable psoriasis data from ICOTYDE

Published on 10/04/2026 at 11:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock was last at USD 256.03 on October 2, 2026, down 1.02 percent. ICOTYDE data showed 70 percent skin clearance at Week 112.

Black and white documentary photograph of a bearded pediatrician pressing a stethoscope to the chest of a young smiling child seated on an examination table, soft window light from the left, fine film grain, clinical room softly blurred in the background — Johnson Kinderarzt untersucht ein Kind mit Stethoskop, US4781601046 steht für humane Medizin, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) was last at USD 256.03 on the NYSE on October 2, 2026, down 1.02 percent from the prior close. The market move came as Johnson & Johnson reported new two-year ICOTYDE data dated October 2, 2026.

Psoriasis data reach two years

The Phase 3 ICONIC-TOTAL study showed that 70 percent of treated patients had clear or almost clear skin at Week 112, compared with 57 percent at Week 16. Site-specific complete clearance reached 60 percent for scalp psoriasis and 89 percent for genital psoriasis at Week 112, according to Johnson & Johnson.

The comparison from Week 16 to Week 112 is the key operating signal: the clear-or-almost-clear rate increased by 13 percentage points. The company said the safety findings through Week 112 remained consistent with the established safety profile.

Quarterly revenue rose 6.6 percent

Johnson & Johnson's Q2 2026 revenue reached USD 25.31 billion, up 6.6 percent year over year, while adjusted EPS was reported at USD 2.90 versus a USD 2.84 consensus estimate, MarketBeat reported. Fiscal 2026 adjusted EPS guidance stood at USD 11.600-11.750.

The next quantified checkpoint is Q3 reporting. MarketBeat lists October 13, 2026, for the Q3 2026 report before the market opens. Stelara biosimilar competition remains a counter-factor for near-term pharmaceutical growth.

Consensus target sits 7.1 percent higher

A 25-analyst consensus carried a Moderate Buy rating and a USD 274.13 average 12-month target on September 29, 2026, according to MarketBeat. That target is 7.1 percent above the USD 256.03 reference price.

Stock stays below yearly high

Johnson & Johnson stock was last at USD 256.03 on the NYSE on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 182.94 to USD 281.07 and market capitalization of USD 617.0 billion. Volume reached 10,176,696 shares.